eHealth Ventures

Managing Partner Talor Sax leads the investment process, supported by a team with backgrounds across healthcare, technology, and venture capital. As a focused seed fund, the investment committee is deliberately lean. The firm's partnership with Cleveland Clinic and Maccabi Health Services also provides clinical-advisory input during diligence.

Deal flow originates inside the Israeli digital-health ecosystem — hospitals, research labs, military medical-corps alumni, and serial health-tech founders. The partnership with Maccabi Health Services offers direct line of sight into clinical needs inside Israel's second-largest HMO. Additional sourcing comes from the Mayo Clinic-Israel initiative and the newly established California accelerator channel.

eHealth Ventures makes direct seed-stage equity investments, typically ranging from $500,000 to $2 million, with capital reserved for follow-on rounds through Series A. The firm does not function as a fund of funds nor participate in third-party LP commitments; the vehicle is structured as a conventional early-stage venture capital fund with a health-sector mandate.

The firm publicly focuses on digital health and will typically avoid therapeutics, medical devices, and drug discovery — areas that require FDA trial timelines and capital intensity mismatched with a seed-stage technology fund. It also stays away from general SaaS and enterprise software that lacks a clear clinical end-user or regulatory dimension.

eHealth Ventures routinely syndicates rounds with other digital-health or generalist Israel-focused funds. The firm's club-deal behavior reflects its position as a domain specialist that can bring clinical validation assets to a cap table. Co-investors in its portfolio rounds have included both Israeli and US venture firms, though specific syndicate partners are not systematically disclosed.

Both organizations are limited partners in the fund and serve as clinical-pilot testbeds for portfolio companies. This arrangement gives eHealth Ventures early access to US hospital infrastructure via Cleveland Clinic and to Israel's integrated HMO data environment via Maccabi. The relationships are arm's-length LP commitments, not joint ventures or clinical subsidiaries.

The firm enters at pre-seed and seed stage, occasionally participating in later seed rounds where clinical validation is already underway. Check sizes run from $500,000 to $2 million. The fund reserves capital for follow-on through Series A and selectively into Series B, but the portfolio construction is anchored to earliest-stage digital-health companies.